Mangalore Refinery and Petrochemicals Limited (MRPL) has been awarded a United States patent for its innovative method of preparing iso-Butyl Benzene (i-BB), marking a significant breakthrough in pharmaceutical ingredient synthesis. The patent, titled "Isobutyl Benzene and a Process for Synthesis of Isobutyl Benzene by using a Catalyst" and dated May 27, 2025, establishes MRPL's global footprint in pharmaceutical technology innovation.
Innovative Production Technology
The patented process centers on a side-chain alkylation method that converts a low-value captive stream into iso-Butyl Benzene using a specially engineered catalyst developed at MRPL's Innovation Centre. This catalyst is designed to achieve high conversion efficiency and selectivity toward the i-BB product, representing a major technological advancement in pharmaceutical intermediate manufacturing.
The development of this technology was achieved through collaboration with CSIR-National Chemical Laboratory (CSIR-NCL), and the company had previously secured an Indian patent for the same process technology, as stated in MRPL's annual report for 2023-24.
Critical Pharmaceutical Applications
Iso-Butyl Benzene serves as an essential raw material in the synthesis of Brufen (ibuprofen), a commonly used non-steroidal anti-inflammatory drug (NSAID) and widely used analgesic. The compound functions as an active pharmaceutical intermediate and key input for pain killers, with additional applications in the perfume industry.
By developing this production process domestically, MRPL aims to reduce dependence on imported intermediates and enhance self-reliance in pharmaceutical ingredient supply. The technology allows the company to manufacture the product using captive feedstock available within MRPL facilities.
Commercial Scale-Up Initiatives
As part of its scale-up efforts, MRPL is currently establishing a pilot plant for i-BB production. This facility represents a key step toward commercial-scale manufacturing and supports the transition from laboratory development to full-scale production capabilities.
The pilot plant development reflects MRPL's strategic focus on advancing technologies relevant to the pharmaceutical and chemical sectors, supporting India's broader goals in local manufacturing and process innovation. This initiative strengthens the company's contribution to the domestic pharmaceutical sector while reducing reliance on imported materials.
